SA
Go ProLog In
ORKA
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
9 analysts·Limited coverage
75
Score
9 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
9100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$75.00
+28.0%
Consensus
$135.50
+131.2%
Bull
$200.00
+241.2%
12-Month Target Range9 analysts
$75.00$135.50$200.00
Current $58.62Consensus
Current Price
$58.62
Upside to Consensus
$76.88

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev—
EPS—
FY2028
Rev—
EPS—
FY2029
Rev—
EPS—

Earnings Surprises

Recent Analyst Actions

Apr 30, 2026Leerink Partners
Oruka Therapeutics price target raised to $120 from $109 at Leerink
Target:$120.00
+76.2%from $68.10
Apr 29, 2026H.C. Wainwright
Oruka Therapeutics price target raised to $120 from $75 at H.C. Wainwright
Target:$120.00
+62.2%from $73.99
Apr 28, 2026UBS
Oruka Therapeutics price target raised to $100 from $75 at UBS
Target:$100.00
+22.8%from $81.42
Apr 27, 2026Wedbush
Oruka Therapeutics price target raised to $165 from $85 at Wedbush
Target:$165.00
+105.8%from $80.16
Apr 27, 2026Barclays
Oruka Therapeutics price target raised to $160 from $78 at Barclays
Target:$160.00
+99.1%from $80.35
Apr 27, 2026Guggenheim
Oruka Therapeutics price target raised to $200 from $125 at Guggenheim
Target:$200.00
+146.6%from $81.11
Apr 27, 2026BTIG
Oruka Therapeutics price target raised to $151 from $78 at BTIG
Target:$151.00
+83.4%from $82.36
Apr 15, 2026Wedbush
Oruka Therapeutics price target raised to $85 from $45 at Wedbush
Target:$85.00
+26.8%from $67.06
Mar 13, 2026BTIG
BTIG Reiterates Buy Rating on Oruka Therapeutics (ORKA): 'Commercial Precedents Continue to Read Through Positively to ORKA-001/2'
Target:$73.00
+92.0%from $38.01
Jan 13, 2026Wedbush
Oruka Therapeutics price target raised to $45 from $42 at Wedbush
Target:$45.00
+48.6%from $30.28
Jan 7, 2026UBS
UBS Starts Oruka Therapeutics (ORKA) at Buy
Target:$50.00
+87.8%from $26.62
Dec 18, 2025Piper Sandler
Oruka Therapeutics initiated with an Overweight at Piper Sandler
Target:$75.00
+164.3%from $28.38
Oct 27, 2025Guggenheim
Oruka Therapeutics initiated with a Buy at Guggenheim
Target:$60.00
+120.2%from $27.25
Oct 27, 2025H.C. Wainwright
Oruka Therapeutics price target lowered to $40 from $45 at H.C. Wainwright
Target:$40.00
+46.8%from $27.25
Oct 13, 2025Barclays
Oruka Therapeutics initiated with an Overweight at Barclays
Target:$48.00
+96.0%from $24.49
Feb 4, 2025Wolfe Research
Oruka Therapeutics initiated with an Outperform at Wolfe Research
Target:$20.00
+46.0%from $13.70
Sep 12, 2024Jefferies
Jefferies Starts Oruka Therapeutics (ORKA) at Buy
Target:$40.00
+53.8%from $26.00
Sep 4, 2024Wedbush
Oruka initiated with an Outperform at Wedbush
Target:$40.00
+56.9%from $25.50

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance